title: Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.
abstract: Women experience a decline in estrogen and androgen levels after natural or surgically induced menopause, effects that are associated with a loss of sexual desire and bone mineral density. Studies in our laboratories have shown the beneficial effects of selective androgen receptor modulators (SARMs) in the treatment of osteoporosis and muscle wasting in animal models. A series of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-trifluoromethyl-phenyl)-propionamide analogs was synthesized to evaluate the effects of B-ring substitutions on in vitro and in vivo pharmacologic activity, especially female sexual motivation. The androgen receptor (AR) relative binding affinities ranged from 0.1 to 26.5% (relative to dihydrotestosterone) and demonstrated a range of agonist activity at 100 nM. In vivo pharmacologic activity was first assessed by using male rats. Structural modifications to the B-ring significantly affected the selectivity of the SARMs, demonstrating that single-atom substitutions can dramatically and unexpectedly influence activity in androgenic (i.e., prostate) and anabolic (i.e., muscle) tissues. (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro,4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide (S-23) displayed full agonist activity in androgenic and anabolic tissues; however, the remaining SARMs were more prostate-sparing, selectively maintaining the size of the levator ani muscle in castrated rats. The partner-preference paradigm was used to evaluate the effects of SARMs on female sexual motivation. With the exception of two four-halo substituted analogs, the SARMs increased sexual motivation in ovariectomized rats, with potency and efficacy comparable with testosterone propionate. These results indicate that the AR is important in regulating female libido given the nonaromatizable nature of SARMs and it could be a superior alternative to steroidal testosterone preparations in the treatment of hypoactive sexual desire disorder.
authors.affiliation: Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, Ohio, USA.
authors.forename: Amanda
authors.initials: A
authors.lastname: Jones
authors.forename: Dong Jin
authors.initials: DJ
authors.lastname: Hwang
authors.forename: Charles B
authors.initials: CB
authors.lastname: Duke
authors.forename: Yali
authors.initials: Y
authors.lastname: He
authors.forename: Anjaiah
authors.initials: A
authors.lastname: Siddam
authors.forename: Duane D
authors.initials: DD
authors.lastname: Miller
authors.forename: James T
authors.initials: JT
authors.lastname: Dalton
mesh_terms: D000728:Androgens; D000813:Anilides / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001667:Binding, Competitive; D002460:Cell Line; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009919:Orchiectomy; D009929:Organ Size; D010052:Ovariectomy; D011467:Prostate / Q000033:anatomy & histology / Q000187:drug effects; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011944:Receptors, Androgen / Q000502:physiology*; D012737:Sex Factors; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D015533:Transcriptional Activation; D014599:Uterus / Q000033:anatomy & histology / Q000187:drug effects
chemical_list: D000728:Androgens; D000813:Anilides; C538983:N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methylpropanamide; D011944:Receptors, Androgen; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
references.citation: Bioorg Med Chem Lett. 2008 Jun 1;18(11):3431-5
references.pmid: 18442912
references.citation: Mol Pharmacol. 2003 Jan;63(1):211-23
references.pmid: 12488554
references.citation: Xenobiotica. 1996 Feb;26(2):117-22
references.pmid: 8867996
references.citation: J Pharmacol Exp Ther. 2005 Feb;312(2):546-53
references.pmid: 15347734
references.citation: Pharm Res. 2007 Feb;24(2):328-35
references.pmid: 17063395
references.citation: Endocrinology. 2005 Dec;146(12):5444-54
references.pmid: 16166218
references.citation: Bioorg Med Chem Lett. 2008 May 1;18(9):2967-71
references.pmid: 18400499
references.citation: Physiol Behav. 1983 Mar;30(3):437-43
references.pmid: 6683412
references.citation: Endocrinology. 2009 Jan;150(1):385-95
references.pmid: 18772237
references.citation: Horm Behav. 1989 Dec;23(4):473-502
references.pmid: 2691387
references.citation: Am J Obstet Gynecol. 1981 Aug 1;140(7):725-9
references.pmid: 7196155
references.citation: Gynecol Obstet Invest. 1992;34(2):97-101
references.pmid: 1398273
references.citation: J Pharmacol Exp Ther. 2005 Oct;315(1):230-9
references.pmid: 15987833
references.citation: J Clin Endocrinol Metab. 1974 Aug;39(2):340-6
references.pmid: 4278727
references.citation: J Med Chem. 2009 May 14;52(9):2794-8
references.pmid: 19351168
references.citation: J Pharmacol Exp Ther. 2003 Mar;304(3):1323-33
references.pmid: 12604713
references.citation: Endocrine. 2007 Aug;32(1):41-51
references.pmid: 17992601
references.citation: J Med Chem. 2004 Feb 12;47(4):993-8
references.pmid: 14761201
references.citation: Maturitas. 2008 Sep-Oct;61(1-2):17-26
references.pmid: 19434876
references.citation: Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6201-6
references.pmid: 15833816
references.citation: Bioorg Med Chem Lett. 2008 Oct 15;18(20):5567-70
references.pmid: 18805694
references.citation: Psychosom Med. 1987 Jul-Aug;49(4):397-409
references.pmid: 3615768
references.citation: J Pharmacol Exp Ther. 2003 Mar;304(3):1334-40
references.pmid: 12604714
references.citation: Endocrinology. 2005 Nov;146(11):4887-97
references.pmid: 16099859
references.citation: Endocrinology. 2007 Jan;148(1):363-73
references.pmid: 17023534
references.citation: Menopause. 2006 Sep-Oct;13(5):770-9
references.pmid: 16932240
references.citation: Ann Intern Med. 2008 Apr 15;148(8):569-77
references.pmid: 18413618
references.citation: Fertil Steril. 2001 Sep;76(3):456-60
references.pmid: 11532464
references.citation: Eur J Med Chem. 2002 Aug;37(8):619-34
references.pmid: 12161060
references.citation: Horm Behav. 1998 Dec;34(3):283-93
references.pmid: 9878277
references.citation: J Clin Endocrinol Metab. 2005 Sep;90(9):5226-33
references.pmid: 16014407
references.citation: Medicine (Baltimore). 1992 Jan;71(1):44-51
references.pmid: 1549058
references.citation: Br J Pharmacol. 2008 May;154(2):440-50
references.pmid: 18414397
references.citation: Obstet Gynecol. 2005 May;105(5 Pt 1):944-52
references.pmid: 15863529
references.citation: Biochem Biophys Res Commun. 1998 Mar 6;244(1):1-4
references.pmid: 9514878
references.citation: Best Pract Res Clin Endocrinol Metab. 2002 Mar;16(1):31-41
references.pmid: 11987896
references.citation: J Med Chem. 2004 Jul 15;47(15):3765-76
references.pmid: 15239655